Joseph D. Rosenblatt

University of Miami — United States

Medicine · Health Sciences

63h-index17.4kcitations384works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(85), T-cell and Retrovirus Studies(60), HER2/EGFR in Cancer Research(58), CAR-T cell therapy research(58), Angiogenesis and VEGF in Cancer(57)

Publications384 total

Mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel induce high complete response rates at day+90 in Relapsed/Refractory large B-cell lymphoma
Blood·2025Open Access
Feasibility and preliminary efficacy of a Mediterranean diet and home-based exercise intervention during chemotherapy for lymphoma survivors: The life-l study
Blood·2025Open Access
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Journal of Clinical Oncology·2025· 4 citedOpen Access
High rate of complete responses induced by platinum-based regimen with BTK inhibitors in Richter syndrome
Blood Advances·2025· 2 citedOpen Access
Absolute and Unconditional Convergence of Series of Ergodic Averages and Lebesgue Derivatives
arXiv (Cornell University)·2025Open Access
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial
The Lancet Haematology·2024· 20 cited
Modeling Lymphoma Angiogenesis, Lymphangiogenesis, and Vessel Co-Option, and the Effects of Inhibition of Lymphoma–Vessel Interactions with an αCD20-EndoP125A Antibody Fusion Protein
Cells·2024· 1 citedOpen Access
5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Blood·2024· 14 citedOpen Access
Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed/Refractory Follicular Lymphoma
Blood·2024· 3 citedOpen Access
Molecular Biology and Pathogenesis of HTLV-II
2024· 1 cited
Supplementary Figure 7 from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling
2024Open Access
FIGURE 6 from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling
2024Open Access
Supplementary Figure 1B from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling
2024Open Access
FIGURE 1 from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling
2024Open Access
Supplementary Table 1-1 from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling
2024Open Access
Supplementary Table 1-4 from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling
2024Open Access
FIGURE 2 from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling
2024Open Access
Supplementary Table 1-3 from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling
2024Open Access
Supplementary Figure 7 from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling
2024Open Access
Supplementary Figure 5 from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling
2024Open Access
page 1 of 20Next →

Frequent Co-authors

Nancy L. Bartlett(7), Anas Younes(6), Ajay K. Gopal(5), Andres Forero‐Torres(5), Joseph M. Connors(5), Dana A. Kennedy(5), Eric L. Sievers(5), Ranjana H. Advani(5), David Parry(5), Terence A. Partridge(5), Irvin S. Y. Chen(5), Scott E. Smith(4), Radhakrishnan Ramchandren(4), Sven de Vos(4), Robert Chen(4), Pauline Brice(4), Michelle A. Fanale(4), Stephen M. Ansell(3), Kerry J. Savage(3), Andreas Engert(3)